Sort
130,381 grants matching “hiv”
Highly Adaptive Epidemic Control Strategies for HIV Prevention in Drug Users
$2,437,500Brandon David Lewis Marshall · Brown University · DP2 · FY2015 · DA
A binational cohort of the intersection between substance use, HIV, and associated comorbidities among people who inject drugs in San Diego, CA
$2,437,310Steffanie A Strathdee · University Of California, San Diego · U01 · FY2025 · DA
AIDS Linked to the IntraVenous Experience (ALIVE)
$2,437,098Shruti H Mehta · Johns Hopkins University · U01 · FY2023 · DA
Novel Strategies to Prevent Malaria and Improve HIV Outcomes in Africa
$2,436,893Diane V Havlir · University Of California, San Francisco · P01 · FY2010 · HD
AIDS Linked to the IntraVenous Experience (ALIVE)
$2,436,595Shruti H Mehta · Johns Hopkins University · U01 · FY2024 · DA
Brooklyn Women's Interagency HIV Study (WIHS) V
$2,436,591Howard Minkoff · Suny Downstate Medical Center · U01 · FY2017 · AI
Lentiviral Gene Therapy for Sickle Cell Disease and Immunodeficiency Disorders
$2,436,444Brian P Sorrentino · St. Jude Children'S Research Hospital · P01 · FY2011 · HL
Case Clinical Trials Unit
$2,436,364Jeffrey M Jacobson · Case Western Reserve University · UM1 · FY2023 · AI
Surviving the HIV Epidemic (S/HE) in metropolitan Washington DC - Advancing knowledge through cohort studies
$2,435,000Seble G Kassaye · Georgetown University · U01 · FY2019 · HL
Atlanta MACS/WIHS Combined Cohort Study Clinical Research Site
$2,435,000Ighovwerha Ofotokun · Emory University · U01 · FY2019 · HL
THE IMPACTA PERU CLINICAL TRIALS UNIT
$2,434,595Jorge Luis Sanchez · Asociacion Civil Impacta Salud Y Educacn · UM1 · FY2013 · AI
HIV PREVENTION PROJECTS
$2,434,358Michael G Harmon · Oklahoma State Department Of Health · U62 · FY2007 · PS
EO-NAT HIV Rapid Point-of-Care Diagnostic Device for Resource-Limited Settings
$2,434,269Ph.d., Daniel Laser · Wave 80 Biosciences, Inc. · N01 · FY2013 · AI
Mentoring Oral Health Research in Louisiana
$2,434,104Louisiana State Univ Hsc New Orleans · P20 · FY2004 · RR
Single Cell Transcriptomic and Epigenomic Dissection of Opioid and Cocaine Responses in HIV
$2,433,874Manolis Kellis · Broad Institute, Inc. · U01 · FY2023 · DA
Protein Trafficking In The Endosomal-Lysosomal System
$2,433,234Juan Bonifacino · Eunice Kennedy Shriver National Institute Of Child Health & Human Development · Z01 · FY2008 · HD
HIV-1 Vaccines Designed to Induce Mucosal Immunity
$2,433,228University Of California Davis · U19 · FY2003 · AI
HIV/SIV Data Base and Analysis Unit
$2,431,941Bette Korber · National Institute Of Allergy And Infectious Diseases · Y01 · FY2019 · AI
CD40L adjuvanted clade C DNA and MVA HIV vaccines
$2,431,541Rama Rao Amara · Emory University · U19 · FY2016 · AI
Microglial IFN-y production is a key defense system to coordinate both innate and T cell-mediated protective immunity in the brain for preventing reactivation of cerebral Toxoplasma infection
$2,431,364Yasuhiro Suzuki · University Of Kentucky · R01 · FY2025 · AI
An AAV-mediated functional cure and its impact on the reservoir
$2,431,122Michael R. Farzan · Boston Children'S Hospital · U19 · FY2024 · AI
NEUROLOGIC AIDS RESEARCH CONSORTIUM
$2,430,942David B Clifford · Washington University · U01 · FY2008 · NS
Mechanisms Underlying Clearance of Persistent Infections
$2,430,939Dorian McGavern · National Institute Of Neurological Disorders And Stroke · ZIA · FY2018 · NS
Northwestern University Clinical Trial Unit
$2,430,318Robert L. Murphy · Northwestern University At Chicago · U01 · FY2009 · AI
PS10-1001, HIV PREVENTION PROJECTS
$2,430,267Jan Fox · Oklahoma State Department Of Health · U62 · FY2011 · PS